ArkeaBio secures $15m for livestock methane vaccine

ArkeaBio raised $15 million in Series A2 funding to scale a livestock methane reduction vaccine, cutting headcount by one-third while targeting emissions that account for 14-18% of global greenhouse g

ArkeaBio secured $15 million in Series A2 funding led by AgriZeroNZ and Breakthrough Energy, while reducing its workforce by approximately one-third. The company targets two specific methanogen species—representing 50% and the second largest share of rumen microbes—to reduce livestock methane emissions, which constitute 14-18% of global greenhouse gas emissions. Its first product aims for 10-15% reduction in methane emissions from dairy cattle, with a vaccine administration interval of three months. ArkeaBio plans to submit a regulatory application to New Zealand in 2027 and expects commercialization by 2028.

This approach addresses a critical vulnerability in the food system: livestock methane emissions. By targeting the microbial processes in animal digestion, the technology could lower emissions from a source that drives climate instability and food system fragility. However, the current product’s impact is limited to emissions reduction only—productivity gains are not claimed until methane reduction exceeds 30%. Vaccine efficacy and interval duration also vary by livestock type.

For food security, this could eventually lower emissions from a major food system vulnerability. But immediate benefits remain constrained by the product’s narrow scope and the 30% threshold for productivity effects. What matters next is whether New Zealand’s regulatory timeline holds and whether the vaccine’s scalability matches the 10-15% reduction target across diverse livestock populations.

Source: AgFunder News